Ezetrol Side Effects Update
August 24, 2005 at 3:29 pm | In Prescribing Extra - Drugs |
Print
| 3 Comments
The Summary of Product Characteristics for Ezetimibe (Ezetrol) has been updated recently following notification of some rare adverse events in patients taking this drug.
There have been reports of myopathy and rhabdomyolysis, most of these were in patients who were also taking a statin although some were on monotherapy with Ezetimibe.
Additionally, hepatitis has been reported as well as interactions with Warfarin and Ciclosporin.
Action: Patients on Ezetimibe should be informed to notify a clinician of any unexplained muscle pain or weakness. If myopathy is suspected then all drugs likely to be causal should be stopped (including statins and Ezetimibe).
Patients who are on Warfarin or Ciclosporin should be carefully monitored (for INR and therapeutic blood level respectively) during treatment with Ezetimibe.
Bookmark in del.icio.us
I have been taking this for 2 years and in the last few months have had hip pains (not all the time) Doctor didnt seem to think it was a problem perhaps age – I am 65 and only take osteopororosis monthly tablet.
Bit worrying re hip pain – intermittent.
Comment by S Avoth — August 24, 2008 #
I also have been on this drug for 2 years and have started to get very bad hip and knee pains had x-rays no bone degeneration doctor puzzled but at my suggestion I am having a break from this drug for a month been off it 3 weeks and there seems to be a little improvement I dont think I will be taking it again. I am 67
Comment by s.attenborrow — August 25, 2008 #
If you suspect that any problem is related to your medication it is always worth chatting this through with your doctor to see if you can trial stop the medication to see if the problem resolves.
If it doesn’t change you’ll know it’s not the drug and can continue to take it from a more reassured understanding and even if it does improve it is worth trying the medicine again to see if the problem returns. Only if it does return the same as before is it worth considering an alternative.
Comment by Matthew Robinson — August 26, 2008 #